Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Alcohol Clin Exp Res. 2020 May 25;44(7):1431–1443. doi: 10.1111/acer.14352

Table 3.

Summary of adverse events reported by at least 10% of participants in either arm of the study

MedDRA SOC/Preferred term Placebo (n = 24) Varenicline (n = 23) p
Nausea 4 (16.7%) 10 (43.5%) 0.060
Abnormal dreams 5 (20.8%) 7 (30.4%) 0.517
Nasopharyngitis 6 (25.0%) 1 (4.3%) 0.097
Bright urine 1 (4.2%) 3 (13.0%) 0.348

Note. Multiple occurrences of a specific adverse event for a participant were counted once in the frequency for the adverse event.